Jamie Swaney, Ph.D., Vice President of Fibrosis and Translational Biology at Lassen Therapeutics, will discuss the antibody-mediated blockade of interleukin-11 signaling for idiopathic pulmonary fibrosis and other fibrosing lung diseases. His presentation will focus on the background of IL11/IL11RA and their role in lung fibrosis and other fibrotic diseases, cell-specific expression and upregulation of IL11 in lung fibrosis, development and characterization of anti-IL11 receptor antibodies to treat lung fibrosis and use of primary cells, in vivo models and ex vivo translational assays to interrogate anti-IL11 therapy as a treatment for lung fibrosis. Dr. Swaney has more than 17 years of drug development experience in tissue fibrosis/remodeling and inflammation. Prior to joining Lassen, he was Executive Director and head of fibrosis at Metacrine, leading small molecule programs for NASH liver fibrosis. Dr. Swaney has contributed to several patents and authored multiple peer-reviewed publications. He received a Ph.D. in Molecular Pathology from the University of California at San Diego, and holds an M.S. from the University of San Diego and a B.S. from the University of California at Santa Barbara.